Perlegen Sciences and 454 Life Sciences (now owned by Roche [1]) have teamed up to conduct large scale genetic re-sequencing in DNA samples collected from people with specific responses to an undisclosed class of drug. The companies hope to identify a specific genetic variation and create a test to administer to patients taking the drug that will determine what their response will be. "This study holds the promise to improve therapeutic outcomes for a vast number of patients," noted Bryan Walser, MD, CEO of Perlegen. Perlegen was a 2003 Fierce 15 [2] company.
- check out the release [3]Â on the deal
Related Articles:
Roche snares 454's sequencing tech in buyout. Report [1]
454 makes big advance in sequencing technology. Report [4]
Perlegen strikes collaboration deal with Genentech. Report [5]
Links:
[1] http://www.fiercebiotech.com/story/roche-snares-454-s-sequencing-tech-in-buyout/2007-03-29
[2] http://www.fiercebiotech.com/Fierce15/2003/perlegen-sciences
[3] http://www.fiercebiotech.com/press-releases/press-release-perlegen-and-454-collaborate-drug-response-sequencing-study
[4] http://www.fiercebiotech.com/story/454-life-sciences-makes-big-advance-in-sequencing-technology/2005-08-01
[5] http://www.fiercebiotech.com/story/perlegen-strikes-collaboration-deal-with-genentech/2006-01-06